Please login to the form below
avibactam
This page shows the latest avibactam news and features for those working in and with pharma, biotech and healthcare.
Shionogi Europe and NHS England agree on antibiotic subscription model
exist. Fetcroja is one of two antimicrobial products – the other being Zavicefta (ceftazidime-avibactam), manufactured by Pfizer – to be selected and made available under the scheme run by NICE and NHS
Latest news
-
NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan
NHS England, the National Institute for Health and Care Excellence (NICE) and the UK Department of Health have concluded an assessment of Pfizer’s Zavicefta (ceftazidime with avibactam) and Shionogi’s
-
Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought
Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle
-
Pfizer launches new antibiotic Zavicefta in UK and Germany
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
-
AZ slims down again with sale of antibiotics to Pfizer
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
-
AZ gets EU green light for new antibiotic Zavicefta
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization. ... AZ and Actavis are also testing avibactam in combination with other beta
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
